Sepracor gets FDA input on antidepressant plans
This article was originally published in Pharmaceutical Approvals Monthly
Sepracor is "evaluating the possible initiation" of a Phase III registrational trial for its serotonin/norepinephrine reuptake inhibitor SEP-227162, after hearing from FDA that the agency has agreed with key elements of Sepracor's plans. In 2008, the firm submitted a briefing package to the agency outlining a proposal to conduct an abbreviated Phase III program for the dual reuptake inhibitor. Sepracor has also fully enrolled a Phase II study for its novel triple reuptake inhibitor for depression, SEP-225289, with clinical results anticipated in the third quarter
You may also be interested in...
If President Trump appoints, and the Senate approves, a new conservative justice for the Supreme Court to replace Ruth Bader Ginsberg, Affordable Care Act coverage could disappear. See what Kyle Sampson, a partner with the Washington, DC law firm King & Spalding said about it here.
Join us for an audio roundup of major events in the global biopharma industry over the past week, as reported by Scrip.
Keeping Track: New Nucala Indication; BMS’ Ide-Cel Clears Filing Hurdle; First Applications From Telix And ADC Therapeutics
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.